

Hemagglutinin (HA) Protein Ectodomain from Influenza B Virus, B/Brisbane/60/2008, Recombinant from Baculovirus

Catalog No. NR-56334

This reagent is the tangible property of the U.S. Government.

Product Description:

A recombinant form of the ectodomain of the hemagglutinin (HA) protein from influenza B virus, B/Brisbane/60/2008, Victoria lineage with a hexa-histidine tag was produced in Sf9 insect cells using a baculovirus expression vector system and purified using ion exchange and affinity chromatography. This lot was manufactured and subjected to quality control testing by St. Jude Children’s Research Hospital (SJCRC), Memphis, Tennessee, USA.


Lot: 70050564

Manufacturing Date: 22OCT2021

TEST	SPECIFICATIONS	RESULTS
Appearance	Report results	Opalescent
SDS-PAGE Analysis	Report results	Dominant band of ~ 62 kDa accounting for > 90% of total staining intensity (Figure 1)
Concentration by Bicinchoninic Acid Assay Bovine Serum Albumin (BSA; standard)	Report results	1.08 mg per mL
Final Product Amount per vial Volume per vial	Report results Report results	108 µg 100 µL
Functional Activity Hemagglutination titer using 0.5% turkey red blood cells Western blot analysis with polyclonal anti-HA ¹	Report results Report results	1:512 Reactive (Figure 2)
Filtration	0.2 µm sterile-filtered	0.2 µm sterile-filtered
Endotoxin	Report results	≤ 0.5 EU per mL


¹Using a 1:2000 dilution anti-HA polyclonal goat serum G.642(2010) against B/Florida/04/2006 (Yamagata lineage) virus as primary antibody

Figure 1: SDS-PAGE



Lane 1: Molecular Weight Markers
 Lane 2: BSA, 1.0 µg
 Lane 3: BSA, 2.5 µg
 Lane 4: NR-56334, 1.0 µg (pre-vial)
 Lane 5: NR-56334, 2.5 µg (pre-vial)
 Lane 6: NR-56334, 1.0 µg (post-vial)
 Lane 7: NR-56334, 2.5 µg (post-vial)

Figure 2: Western Blot with Polyclonal Anti-HA



Lane 1: Molecular Weight Markers
 Lane 2: BSA, 1.0 µg
 Lane 3: BSA, 2.5 µg
 Lane 4: NR-56334, 1.0 µg (pre-vial)
 Lane 5: NR-56334, 2.5 µg (pre-vial)
 Lane 6: NR-56334, 1.0 µg (post-vial)
 Lane 7: NR-56334, 2.5 µg (post-vial)

/Sonia Bjorum Brower/
 Sonia Bjorum Brower

06 SEP 2022

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by the contributor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

